格菲妥单抗联合方案的临床前进展:非霍奇金淋巴瘤的新前沿
该临床前研究在人源化淋巴瘤模型中探讨格菲妥单抗(CD20×CD3 T细胞衔接器)联合标准化疗、无化疗双共刺激抗体、检查点抑制剂及调节性T细胞清除等方案的抗肿瘤效果。联合R-CHP-Pola或Pola显示强协同作用,在CD20低表达和异质性模型中优势明显,患者来源外周血单个核细胞中T细胞功能持续。
要点
- 格菲妥单抗联合R-CHP-Pola或Pola在临床前模型中显示强协同抗肿瘤疗效,肿瘤快速退缩并减少肿瘤细胞增殖。
- 联合吉西他滨/奥沙利铂增强瘤内T细胞数量与活化并减少耗竭,在CD20低表达和异质性模型中优势明显。
- CD19靶向4-1BBL和CD19-CD28等无化疗组合增强格菲妥单抗活性,双共刺激方案显示协同作用。
核心结论
- 这些发现凸显格菲妥单抗与标准治疗及创新联合方案整合的多功能性,可应对耐药并改善患者结局。
- 临床前研究为正在进行和未来的临床试验提供坚实基础,强调需量身定制基于T细胞衔接器的联合治疗,以在淋巴瘤治疗中最大化疗效并最小化毒性。
研究设计与样本
- 临床前研究,在人源化淋巴瘤模型中评估格菲妥单抗(CD20×CD3 T细胞衔接器)联合方案。
- 转化研究使用患者来源外周血单个核细胞接受格菲妥单抗联合化疗。
- 试验注册于www.clinicaltrials.gov,注册号#NCT04408638和NCT03467373。
主要发现
- 格菲妥单抗联合R-CHP-Pola(利妥昔单抗、环磷酰胺、多柔比星、泼尼松和维泊妥珠单抗)化疗或Pola显示强协同抗肿瘤疗效,肿瘤快速退缩并减少肿瘤细胞增殖。
- 格菲妥单抗联合吉西他滨/奥沙利铂也显示强疗效,增强瘤内T细胞数量、活化并减少耗竭。
- 上述联合在CD20低表达和异质性表达模型中尤其有利,促进快速肿瘤减负和清除CD20低/CD20-细胞。
- 患者来源外周血单个核细胞接受格菲妥单抗联合化疗的转化研究显示,在延长治疗周期中T细胞功能持续。
- CD19靶向4-1BBL和CD19-CD28等无化疗组合放大格菲妥单抗活性,尤其在CD20高表达和同质性表达肿瘤模型中,双共刺激方法显示协同作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell engagers (TCEs) are transformative therapeutics in hematologic malignancies, including non-Hodgkin lymphoma. Initially approved for relapsed/refractory disease settings, TCEs are now explored in first-line and second-line settings, often combined with standard-of-care (SOC) treatments, including chemotherapy and antibody-drug conjugates. This study investigates glofitamab (CD20×CD3 TCE) combinations in preclinical humanized lymphoma models, addressing heterogeneity of tumor antigen expression, immune evasion, and T-cell exhaustion. Combining glofitamab with R-CHP-Pola (rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin) chemotherapy or Pola demonstrated strong synergistic antitumor efficacy with rapid tumor regression and reduced tumor cell proliferation. Glofitamab combination with gemcitabine/oxaliplatin also demonstrated strong efficacy, enhancing intratumor T-cell number, activation, and reduced exhaustion. These combinations were particularly advantageous in models with low and heterogeneous CD20 expression, facilitating rapid tumor debulking and elimination of CD20-low/CD20- cells. Translational studies with patient-derived peripheral blood mononuclear cells receiving glofitamab combination with chemotherapies demonstrated sustained T-cell functionality throughout extended treatment cycles. Novel chemotherapy-free combinations, including CD19-targeted 4-1BBL and CD19-CD28, amplified glofitamab activity, especially in CD20 high- and homogenous-expressing tumor models, with dual costimulatory approaches revealing synergy. In addition, the combination with checkpoint inhibitors (programmed cell death protein 1/Lag3-bispecific antibody) and regulatory T-cell depletion (α-CD25) emerged as promising approaches for enhanced efficacy and to sustain T-cell functionality. These findings highlight the versatility of glofitamab when integrated with SOC and innovative combinations, addressing resistance and improving patient outcomes. The preclinical investigations provide a strong foundation for ongoing and future clinical trials, emphasizing the need to tailor TCE-based combination therapies to maximize efficacy while minimizing toxicity in lymphoma treatment. These trials were registered at www.clinicaltrials.gov as #NCT04408638 and NCT03467373.
引用
- Sam J, Leclercq-Cohen G, Gebhardt S, et al. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025. PMID: 40749164. doi:10.1182/blood.2025028863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。